Mei Ri Jing Ji Xin Wen·2025-10-30 10:32Core Viewpoint - The company, Saiseng Pharmaceutical, announced plans to sell part of its trading financial assets, specifically shares in Beijing Lvzhu Biotechnology and Beijing Kangle Weishi Biotechnology, based on market conditions [1] Company Summary - Saiseng Pharmaceutical holds approximately 13.75 million shares of Lvzhu Biotechnology, accounting for 6.79% of its total share capital, and about 1.36 million shares of Kangle Weishi, representing 0.4855% of its total share capital [1] - For the year 2024, the company's revenue composition is heavily weighted towards the pharmaceutical manufacturing sector, which constitutes 99.63% of its total revenue, with other businesses making up only 0.37% [1] - As of the report date, Saiseng Pharmaceutical has a market capitalization of 5.6 billion yuan [1]